Sutro Biopharma Inc. Common Stock (STRO)
Stock · NASDAQ · Health Care
$10.92as of 10/16/2026
Price chart
Active signals
STRO Signal Track Record
How signals performed across all stocks →What STRO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -1.8% | 48% | September 11, 2026 |
| Bollinger Band Breakdown | 25 | +0.6% | 52% | October 9, 2026 |
| Bollinger Band Breakout | 21 | -8.4% | 33% | June 29, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +3.7% | 63% | August 12, 2026 |
| Any 20-session window (baseline) | -1.6% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STRO
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including no…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 128
- Website
- www.sutrobio.com/
Fundamentals
- 1-day range
- $10.59$11.47
- Market cap
- $400.18M
- P/E (trailing)
- —
- P/E (forward)
- -1.76
- EPS (trailing)
- $-17.32
- Dividend yield
- —
- Beta
- 1.47
- Avg. volume
- 297.8K
How Sutro Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Sutro Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Hans-Peter Gerber · September 18, 2026 · Option Exercise3.8K
- Hans-Peter Gerber · September 18, 2026 · Tax Withholding1.3K @ $15.34
- Petree Daniel H · June 5, 2026 · Grant10.0K
- Connie Matsui · June 5, 2026 · Grant10.0K
- PANEK JAMES P · June 5, 2026 · Grant10.0K
- Hunter Heidi · June 5, 2026 · Grant10.0K
- Dybbs Michael · June 5, 2026 · Grant10.0K
- Wigginton Jon Marc · June 5, 2026 · Grant10.0K
- Jagpal Sukhi · June 5, 2026 · Grant10.0K
- Lobacki Joseph M · June 5, 2026 · Grant10.0K
- Gregory K. Chow · June 2, 2026 · Option Exercise2.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 14.05M
- Total value held
- $341.08M
- Institutional holders
- 69
- Unknown1.25M
- Unknown1.07M
- Unknown1.06M
- Unknown872.6K
- Unknown801.1K
- Unknown720.4K
- Unknown715.3K
- Unknown715.3K
- Unknown715.3K
- Unknown692.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Sutro Biopharma Names New Business Development SVP
Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.
Sutro Biopharma Names New Business Development SVP. Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.